Literature DB >> 10903653

Chlamydia pneumoniae IgG titres and coronary heart disease: prospective study and meta-analysis.

J Danesh1, P Whincup, M Walker, L Lennon, A Thomson, P Appleby, Y Wong, M Bernardes-Silva, M Ward.   

Abstract

OBJECTIVE: To examine the association between coronary heart disease and serum markers of chronic Chlamydia pneumoniae infection.
DESIGN: "Nested" case-control analysis in a prospective cohort study and an updated meta-analysis of previous relevant studies.
SETTING: General practices in 18 towns in Britain. PARTICIPANTS: Of the 5661 men aged 40-59 who provided blood samples during 1978-80, 496 men who died from coronary heart disease or had non-fatal myocardial infarction and 989 men who had not developed coronary heart disease by 1996 were included. MAIN OUTCOME MEASURES: IgG serum antibodies to C pneumoniae in baseline samples; details of fatal and non-fatal coronary heart disease from medical records and death certificates.
RESULTS: 200 (40%) of the 496 men with coronary heart disease were in the top third of C pneumoniae titres compared with 329 (33%) of the 989 controls. The corresponding odds ratio for coronary heart disease was 1.66 (95% confidence interval 1.25 to 2.21), which fell to 1.22 (0.82 to 1.82) after adjustment for smoking and indicators of socioeconomic status. No strong associations were observed between C pneumoniae IgG titres and blood lipid concentrations, blood pressure, or plasma homocysteine concentration. In aggregate, the present study and 14 other prospective studies of C pneumoniae IgG titres included 3169 cases, yielding a combined odds ratio of 1. 15 (0.97 to 1.36), with no significant heterogeneity among the separate studies (chi(2)=10.5, df=14; P>0.1).
CONCLUSION: This study, together with a meta-analysis of previous prospective studies, reliably excludes the existence of any strong association between C pneumoniae IgG titres and incident coronary heart disease. Further studies are required, however, to confirm or refute any modest association that may exist, particularly at younger ages.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10903653      PMCID: PMC27437          DOI: 10.1136/bmj.321.7255.208

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  24 in total

1.  The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring IgG antibodies against Chlamydia pneumoniae.

Authors:  Y K Wong; J M Sueur; C H Fall; J Orfila; M E Ward
Journal:  J Clin Pathol       Date:  1999-02       Impact factor: 3.411

2.  Relation of C pneumoniae antibodies to ischaemic heart disease. Finnish study finds significant association between raised IgG, but not IgA, titres and mortality.

Authors:  L von Hertzen; R Isoaho; S L Kivelä; P Saikku
Journal:  BMJ       Date:  1999-12-11

Review 3.  Chronic infections and coronary heart disease: is there a link?

Authors:  J Danesh; R Collins; R Peto
Journal:  Lancet       Date:  1997-08-09       Impact factor: 79.321

4.  Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

Authors:  P Saikku; M Leinonen; K Mattila; M R Ekman; M S Nieminen; P H Mäkelä; J K Huttunen; V Valtonen
Journal:  Lancet       Date:  1988-10-29       Impact factor: 79.321

5.  Persistent infection and vascular disease: a systematic review.

Authors:  J Danesh; P Appleby
Journal:  Expert Opin Investig Drugs       Date:  1998-05       Impact factor: 6.206

6.  Chlamydia pneumoniae infection and mortality from ischaemic heart disease: large prospective study.

Authors:  N J Wald; M R Law; J K Morris; X Zhou; Y Wong; M E Ward
Journal:  BMJ       Date:  2000-07-22

7.  Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study.

Authors:  F J Nieto; A R Folsom; P D Sorlie; J T Grayston; S P Wang; L E Chambless
Journal:  Am J Epidemiol       Date:  1999-07-15       Impact factor: 4.897

8.  Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not.

Authors:  J M Ossewaarde; E J Feskens; A De Vries; C E Vallinga; D Kromhout
Journal:  Epidemiol Infect       Date:  1998-02       Impact factor: 2.451

9.  Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study.

Authors:  P Saikku; M Leinonen; L Tenkanen; E Linnanmäki; M R Ekman; V Manninen; M Mänttäri; M H Frick; J K Huttunen
Journal:  Ann Intern Med       Date:  1992-02-15       Impact factor: 25.391

10.  Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland.

Authors:  H Miettinen; S Lehto; P Saikku; S M Haffner; T Rönnemaa; K Pyörälä; M Laakso
Journal:  Eur Heart J       Date:  1996-05       Impact factor: 29.983

View more
  45 in total

Review 1.  Sifting the evidence-what's wrong with significance tests?

Authors:  J A Sterne; G Davey Smith
Journal:  BMJ       Date:  2001-01-27

2.  Replicate PCR testing and probit analysis for detection and quantitation of Chlamydia pneumoniae in clinical specimens.

Authors:  M Smieja; J B Mahony; C H Goldsmith; S Chong; A Petrich; M Chernesky
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

3.  Heart disease and the inflammatory response.

Authors:  W Koenig
Journal:  BMJ       Date:  2000-07-22

Review 4.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

Review 5.  Role of infectious and immune factors in coronary and cerebrovascular arteriosclerosis.

Authors:  Claudia Stöllberger; Josef Finsterer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

Review 6.  Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review.

Authors:  R Padwal; S E Straus; F A McAlister
Journal:  BMJ       Date:  2001-04-21

7.  Detection and differentiation of chlamydiae by fluorescence in situ hybridization.

Authors:  Sven Poppert; Andreas Essig; Reinhard Marre; Michael Wagner; Matthias Horn
Journal:  Appl Environ Microbiol       Date:  2002-08       Impact factor: 4.792

8.  Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers.

Authors:  Alyson J Littman; Lisa A Jackson; Emily White; Mark D Thornquist; Charlotte A Gaydos; Thomas L Vaughan
Journal:  Clin Diagn Lab Immunol       Date:  2004-05

9.  Impact of serological methodology on assessment of the link between Chlamydia pneumoniae and vascular diseases.

Authors:  Boulos Maraha; Martin den Heijer; Jan Kluytmans; Marcel Peeters
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

Review 10.  Inhaled corticosteroids in chronic obstructive pulmonary disease: is there a clinical benefit?

Authors:  S F Paul Man; Don D Sin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.